NCT01536327|Withdrawn
Study Stopped
Transitioned to BioMetabol
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease
BioMeta
Loading search results
Transitioned to BioMetabol
BioMeta
Sponsor study identifier
observational
0
4 countries
5
Study Start
August 20, 2018
Actual (reported)Primary Completion
February 28, 2021
Actual (reported)Study Completion
February 28, 2021
Actual (reported)Development of a new MS-based biomarker for the early and sensitive diagnosis of Metachromatic Leu-kodystrophy disease from blood (plasma)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 21, 2012
Actual (reported)February 22, 2012
Actual (reported)August 20, 2018
Actual (reported)February 28, 2021
Actual (reported)February 28, 2021
Actual (reported)Development of a new MS-based biomarker for the early and sensitive diagnosis of metachromatic leukodystrophy disease from the blood
New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.
24 month
Testing for clinical robustness, specificity and long-term stability of the biomarker
36 months
Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
Children's Hospital, Faculty of Medicine, Ain Shams University
Cairo, 55131, Egypt
Centogene AG
Rostock, 18055, Germany
Amrita Institute of Medical Sciences & Research Centre
Kochi, Kerala, 682041, India
Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)
Mumbai, 400705, India
Lady Ridgeway Hospital for Children
Colombo, 00800c, Sri Lanka
For the development of the new biomarkers using the technique of mass-spectometry, 10 ml EDTA blood sample and/or a dry blood spot filter card-blood sample will be taken from the patient. To prove the correct Metachromatic Leukodystrophy diagnosis in those patients where up to the enrolment in the study no genetic testing has been done, sequencing of Metachromatic Leukodystrophy will be done as routine diagnostic. The analyses will be done at the: Centogene AG Am Strande 7 18055 Rostock Germany
Peter Bauer, Prof.
Centogene GmbH
0 participants (actual enrollment reported by the registry).
First Submitted
February 21, 2012
First Posted
February 22, 2012
Study Start
August 20, 2018
Actual (reported)Safety Evaluation of Functional Electrical Stimulation (FES) Cycling in Intensive Care Unit Patients
Contact the study team to confirm eligibility.
Primary Completion
February 28, 2021
Actual (reported)Study Completion
February 28, 2021
Actual (reported)Last Updated
February 13, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: